Health Care Sector Update for 08/29/2017: IMGN,JAZZ,JUNO,ACOR

Top Health Care Stocks

JNJ +0.30%

PFE -0.01%

ABT -0.24%

MRK -0.33%

AMGN +0.30%

Health care stocks have turned narrowly higher again this afternoon, with the NYSE Health Care Index adding slightly more than 0.1% in value today, recouping a small rise earlier Tuesday, while shares of health care companies in the S&P 500 were up just over 0.2% as a group.

In company news, ImmunoGen ( IMGN ) Tuesday rose as much as 22% higher. climbing to within 13 cents of its 52-week high of $8.04 a share after the biotech company working to develop cancer vaccines today announced a collaboration pact worth at least $175 million with Jazz Pharmaceuticals ( JAZZ ) to develop and commercialize antibody-drug conjugate products.

Jazz will pay a $75 million upfront payment to ImmunoGen and up to $100 million over the next seven years in development funding the antibody-drug conjugate programs. In exchange, Jazz gains exclusive global opt-in rights for the development and commercialization of two early-stage, hematology-related antibody conjugate programs as well as an additional program to be designated during the term of the agreement.

Jazz also may exercise its opt-in rights to acquire a prospective product at any time prior to the start of a Phase III clinical trial by paying a fee in the mid-double digits millions of dollars. That amount would rise to the low triple-digit millions of dollars prior to the companies applying for a biologics license.

Immunogen also will be eligible for additional milestone payments plus tiered royalties as a percentage of sales.

In other sector news,

(+) JUNO, Wedbush Morgan raises investment recommendation to Outperform from Neutral.

(-) ACOR, Receives a letter from the FDA refusing to file the company’s new drug application for its Inbrija investigational treatment for patients with Parkinson’s disease already taking a carbidopa/levodopa drug regimen.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

twenty − 2 =